论文部分内容阅读
目的探讨前列地尔联合坎地沙坦治疗糖尿病肾病蛋白尿的临床疗效。方法 86例糖尿病肾病蛋白尿患者,将其按照治疗方案的不同分为观察组和对照组,各43例。观察组实施前列地尔和坎地沙坦联合治疗,对照组患者只进行常规降糖治疗,对比两组患者肾功能指标控制水平和尿蛋白排泄率。结果治疗后观察组血肌酐和尿素氮分别为(79.65±8.64)μmol/L和(11.25±3.69)μmol/L,尿蛋白排泄率为(42.18±19.26)μg/min;对照组血肌酐和尿素氮分别为(94.64±11.26)μmol/L和(19.37±3.82)μmol/L,尿蛋白排泄率为(143.68±51.28)μg/min。两组比较差异有统计学意义(P<0.05)。结论前列地尔联合坎地沙坦治疗糖尿病肾病,减少蛋白尿的临床疗效确切,尿蛋白排泄明显减少,且部分患者肾功能可得到有效改善,值得在临床上推广使用。
Objective To investigate the clinical efficacy of alprostadil combined with candesartan in the treatment of diabetic nephropathy proteinuria. Methods A total of 86 patients with diabetic nephropathy and proteinuria were divided into observation group and control group according to the different treatment regimens, 43 cases in each group. Patients in the observation group were treated with alprostadil and candesartan, and patients in the control group were treated with regular hypoglycemic treatment only. The levels of renal function control and urinary protein excretion were compared between the two groups. Results Serum creatinine and urea nitrogen in the observation group were (79.65 ± 8.64) μmol / L and (11.25 ± 3.69) μmol / L, respectively, and urinary protein excretion rate was (42.18 ± 19.26) μg / Nitrogen was (94.64 ± 11.26) μmol / L and (19.37 ± 3.82) μmol / L, respectively, urinary protein excretion rate was (143.68 ± 51.28) μg / min. The difference between the two groups was statistically significant (P <0.05). Conclusions Alprostadil combined with candesartan in the treatment of diabetic nephropathy, reduce the proteinuria clinical curative effect, urinary protein excretion was significantly reduced, and some patients can be effectively improved renal function, it is worth promoting in clinical use.